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ARTICLE OPEN
A transdiagnostic neuroanatomical signature of psychiatric
illness
Qiyong Gong1,2,3, Cristina Scarpazza4,5, Jing Dai2, Manxi He2, Xin Xu3, Yan Shi3, Baiwan Zhou1, Sandra Vieira4, Eamon McCrory5,
Yuan Ai1, Cheng Yang1, Feifei Zhang1, Su Lui1 and Andrea Mechelli4
Despite an increasing focus on transdiagnostic approaches to mental health, it remains unclear whether different diagnostic
categories share a common neuronatomical basis. The current investigation sought to investigate whether a transdiagnostic set of
structural alterations characterized schizophrenia, depression, post-traumatic stress disorder, and obsessive-compulsive disorder,
and determine whether any such alterations reﬂected markers of psychiatric illness or pre-existing familial vulnerability. A total of
404 patients with a psychiatric diagnosis were recruited (psychosis, n= 129; unipolar depression, n= 92; post-traumatic stress
disorder, n= 91; obsessive-compulsive disorder, n= 92) alongside n= 201 healthy controls and n= 20 unaffected ﬁrst-degree
relatives. We collected structural magnetic resonance imaging scans from each participant, and tested for transdiagnostic
alterations using Voxel-based morphometry. Inferences were made at p < 0.05 after family-wise error correction for multiple
comparisons. The four psychiatric groups relative to healthy controls were all characterized by signiﬁcantly greater gray matter
volume in the putamen (right: z-score: 5.97, p-value < 0.001; left: z-score: 4.97, p-value= 0.001); the volume of this region was
positively correlated with severity of symptoms across groups (r= 0.313; p < 0.001). Putamen enlargement was also evident in
unaffected relatives compared to healthy controls (right: z-score: 8.13, p-value < 0.001; left: z-score: 9.38, p-value < 0.001). Taken
collectively, these ﬁndings indicate that increased putamen volume may reﬂect a transdiagnostic marker of familial vulnerability to
psychopathology. This is consistent with emerging conceptualizations of psychiatric illness, in which each disorder is understood as
a combination of diagnosis-speciﬁc features and a transdiagnostic factor reﬂecting general psychopathology.
Neuropsychopharmacology (2018) 0:1–7; https://doi.org/10.1038/s41386-018-0175-9
INTRODUCTION
Modern psychiatry is based on the principle that mental disorders
are separate categories with distinct etiologies and clinical
presentations. However, it is well known that several individuals
show clear signs of general psychopathology but do not ﬁt neatly
within the boundaries of any diagnostic categories [1]. Further-
more, it has been recognized for several decades that comorbidity
(the coexistence of two or more disorders) is the rule rather than
the exception in mental health, with half of people who meet
diagnostic criteria for one disorder also meeting criteria for at least
one another disorder [2]. Within existing diagnostic systems,
therefore, it is acknowledged that there are not clear-cut
boundaries between the different categories. For example, in
the Diagnostic Statistical Manual of Mental Disorders (DSM), “there
is no assumption that each category of mental disorder is a
completely discrete entity with absolute boundaries dividing it
from other mental disorders” [3]. Consistent with this notion, an
increasing number of genetic and epidemiological studies are
pointing to large overlap between different psychiatric disorders.
For example, similar sets of genes [4] and environmental risk
factors [5] have been found to underlie a range of diagnostic
categories, including schizophrenia, depression, obsessive-
compulsive disorder (OCD), and post-traumatic stress disorder
(PTSD). These ﬁndings have informed an emerging conceptualiza-
tion of psychiatric illness, in which each disorder is best
understood as a combination of diagnosis-speciﬁc as well as
transdiagnostic features or mechanisms [6–9]. For example, in one
inﬂuential model, this transdiagnostic factor—referred to as factor
p—captures general psychopathology in a manner similar to how
factor g of general intelligence measures performance across a
wide range of seemingly disparate cognitive tasks [9]. Under-
standing the nature of vulnerabilities across psychiatric disorders
may be important in informing the development of transdiagnos-
tic interventions aimed a decreasing risk of psychopathology
across disorders—a key direction for intervention research [10].
If a transdiagnostic factor underlies multiple psychiatric
disorders, then one would expect a common neuroanatomical
signature to characterize different diagnostic categories. Currently,
the neuroimaging literature comprises hundreds of studies on the
neuroanatomical basis of psychiatric disease. The vast majority of
these, however, have compared groups of patients who met
criteria for a speciﬁc disorder with control groups of healthy
individuals. Such studies, while valuable in shedding light on
speciﬁc psychiatric disorders preclude any test as to whether
neuroanatomical alterations are in fact shared across traditional
diagnostic categories. Furthermore, because the vast majority of
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studies did not include unaffected relatives, it has generally not
been possible to establish whether the observed alterations
reﬂected the development of psychiatric illness or pre-existing
familial vulnerability.
Our current understanding as to whether common neuroana-
tomical features characterize different disorders is based on meta-
analyses of studies that were carried out on individual disorders
using different methodologies [11]. Consequently, at present, it is
unclear whether different diagnostic categories have a common
underlying neuroanatomical basis and whether any such marker
reﬂects actual psychiatric illness or pre-existing familial vulner-
ability. A recent study investigate examined the neural basis of
three psychiatric disorders (schizophrenia, bipolar disorder, and
major depression). Critically, this study includes high percentages
of medicated patients, ranging from 37% for major depression to
64% for schizophrenia [12]. This raises the possibility that at least
some of the ﬁndings might be attributed to treatment effects. The
aim of the present investigation was therefore to examine
neuroanatomical alterations across medication-naive individuals
suffering from four psychiatric disorders, including schizophrenia,
depression, PTSD, and OCD. We recruited a total of 404 patients
with a psychiatric diagnosis, including psychosis (n= 129),
unipolar depression (n= 92), PTSD (n= 91), and OCD (n= 92)
and 201 healthy volunteers. In addition, in order to elucidate
whether the transdiagnostic alterations were a marker of current
psychiatric illness or reﬂects pre-existing familial vulnerability, we
also recruited 20 unaffected ﬁrst-degree relatives of patients with
ﬁrst-episode psychosis (FEP). All participants were scanned using
the same scanner and acquisition sequence, ensuring compar-
ability of the data across multiple diagnostic categories. We
hypothesized that a common transdiagnostic neuroanatomical
alteration would characterize all four disorders compared to
healthy controls (HCs). Furthermore, we expected that that the
degree of structural alteration would be related to severity of
symptoms within each illness. Finally, we hypothesized that
alterations in similar brain regions would, at least in part, be
evident in unaffected relatives and therefore reﬂect underlying
familial vulnerability rather than simply a marker of current
psychiatric illness.
MATERIALS AND METHODS
Participants
All participants were recruited as part of a larger cohort study of
psychiatric illness in the Chinese population of Han nationality.
Subsets of the data used here have been used in previous studies
[13–16]. The present investigation was approved by the local
research ethics committee and all participants provided written
informed consent. Exclusion criteria applicable to all participants
included: (i) history of drug or alcohol abuse; (ii) pregnancy; and
(iii) any physical illness such as hepatitis, cardiovascular disease, or
neurological disorder, as assessed by interview and review of
medical records. Further information on each group is provided
below.
First-episode psychosis
In all, 129 patients with FEP were included (Table 1). Diagnosis of
FEP and duration of illness were determined by the consensus of
two experienced clinical psychiatrists using the Structured Inter-
view for the DSM-IV Axis I Disorder, Patient Edition (SCID) [17].
Psychopathology was measured on the day of scanning using the
Positive and Negative Syndrome Scale (PANSS) [18]. At the time of
scanning, all patients were medication-naive; this was assessed by
asking participants whether they had ever taken medication for
mental health issues and examining their clinical records.
Major depressive disorder
Ninety-two participants with major depressive disorder (MDD)
were included (Table 1). Diagnosis of MDD was made with the
SCID [17]. Severity of depression was quantiﬁed using the 17-item
Hamilton Depression Rating Scale (HAM-D [19]). All participants
had a total HAM-D score ≥ 18 on the day of testing. At the time of
scanning, all patients were medication-naive; this was assessed by
asking participants and examining their clinical records.
Post-traumatic stress disorder
Ninety-one participants with PTSD were included (Table 1). These
participants were survivors of the 2008 Sichuan earthquake who
had all physically experienced the earthquake, personally
witnessed death, serious injury, or the collapse of buildings, and
not suffered any physical injury. All participants were assessed
using the PTSD Checklist (PCL) [20] and met threshold criteria (PCL
score ≥ 35) for diagnosis of PTSD on the day of scanning. Patients
were also assessed using the Clinician Administered PTSD scale
[21]. At the time of scanning, all patients were medication-naive;
this was assessed by asking participants and examining their
clinical records.
Obsessive-compulsive disorder
Ninety-two participants with OCD were included (Table 1).
Diagnosis of OCD and assessment of symptom severity were
based on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
and the clinician-rated Y-BOCS symptom checklist [22]. At the time
of scanning, all patients were medication-naive; this was assessed
by asking participants and examining their clinical records.
Healthy controls
In all, 201 HC subjects were included (Table 1). All were recruited
by poster advertisement, and screened using the non-patient
edition of the SCID [17] to conﬁrm the lifetime absence of
Table 1. Demographic and clinical characteristics of participants
FEP
(n= 129)
MDD
(n= 92)
PTSD
(n= 91)
OCD
(n= 92)
HC
(n= 122)
Age (±SEM) 25.00 (0.69) 34.96 (1.25) 42.73 (1.09) 29.97 (0.88) 29.61 (1.30)
Gender 55 M:74 F 43 M:49 F 29 M:62 F 59 M:33 F 78 M:123 F
Years of education (±SEM) 13.00 (0.27) 12.83 (0.60) 7.10 (0.33) 14.16 (0.32) 12.33 (0.29)
Symptom scores (±SEM) PANSS positive: 24.50 (0.56)
PANSS negative: 16.56 (0.69)
PANSS general: 46.54 (0.83)
PANSS total: 95.47 (1.74)
HAM-D: 23.06 (0.39) PCL: 49.28 (1.08)
CAPS: 58.06 (1.28)
Y-BOCS obsession: 12.94 (5.08)
Y-BOCS compulsion: 8.42 (5.31)
Y-BOCS total: 21.38 (0.57)
FEP ﬁrst-episode psychosis, MDD major depressive disorder, PTSD post-traumatic stress disorder, OCD obsessive-compulsive disorder, HC healthy control, PANSS
Positive and Negative Syndrome Scale, PCL PTSD checklist, CAPS Clinician Administered PTSD Scale, HAM-D Hamilton Depression Rating Scale, Y-BOCS Yale-
Brown Obsessive Compulsive Scale, SEM standard error of the mean, M males, F females
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psychiatric illnesses. In addition, these subjects were interviewed
to exclude individuals with a known history of psychiatric illness in
ﬁrst-degree relatives.
Unaffected relatives
To explore whether any transdiagnostic neuroanatomic alterations
detected in the four diagnostic groups were a marker of current
psychiatric illness or reﬂected pre-existing familial vulnerability, we
also recruited 20 unaffected ﬁrst-degree relatives of patients with
a diagnosis of FEP. The absence of psychiatric illness in these
participants was established using the non-patient edition of the
SCID [17].
Data acquisition
High-resolution T1-weighted images were acquired using a 3 T
magnetic resonance imaging (MRI) system (EXCITE, General
Electric, Milwaukee, WI, USA) with a volumetric three-
dimensional spoiled gradient recall sequence (TR= 8.5 ms, TE=
3.4 ms, ﬂip angle= 12°, and slice thickness= 1.0 mm) with an
eight-channel phase array head coil. A ﬁeld of view of 24 cm2 was
used with an acquisition matrix comprising 256 readings of 128
phase-encoding steps, producing 156 contiguous coronal
slices with slice thickness of 1.0 mm and in-plane resolution of
0.47 mm× 0.47 mm.
Data analysis
The T1-weighted volumetric images were pre-processed using
voxel-based morphometry as implemented in SPM12 software
(http://www.ﬁl.ion.ucl.ac.uk/spm) running under Matlab 7.1 (Math
Works, Natick, MA, USA). In particular we used the Diffeomorphic
Anatomical Registration using Exponentiated Lie algebra (DARTEL)
SPM8 toolbox [23]; this involves the creation of a dataset-speciﬁc
template and the segmentation of each individual image using
such template, with the aim of maximizing accuracy and
sensitivity [24]. The following steps were followed: (1) checking
for scanner artifacts and gross anatomical abnormalities for each
subject; (2) setting the image origin to the anterior commissure;
(3) using the DARTEL toolbox to produce a high-dimensional
normalization protocol; (4) checking for homogeneity across the
sample; and (5) using standard smoothing (i.e. 8 mm). A
“modulation step” was also included in the normalization in order
to preserve the information about the absolute gray matter values
[25]. After pre-processing, we obtained smoothed, modulated,
normalized images for each of our four datasets. These were used
to compare patients and controls using an analysis of covariance
(ANCOVA), with age, gender, and total gray matter volume
modeled as covariates of no interest. Neuroanatomical alterations
common to the four diagnostic groups were identiﬁed by
comparing FEP, PTSD, MDD, and OCD patients against HCs (e.g.
FEP, PTSD, MDD, and OCD vs HC) and then using the inclusive
masking option (at p < 0.05 uncorrected) in SPM12 software to
identify those regions that survived the diagnosis-speciﬁc
comparisons (i.e. FEP vs HC; PTSD vs HC; MDD vs HC; and OCD
vs HC). This enabled us to detect alterations in the FEP group that
reﬂect a transdiagnostic feature of psychiatric illness. Statistical
inferences were made at p < 0.05 after family-wise error (FWE)
correction with a minimum extent threshold of 10 voxels. Finally,
in order to elucidate whether transdiagnostic alterations were a
marker of current psychiatric illness or reﬂected pre-existing
familial vulnerability, we performed statistical comparison
between unaffected relatives and HCs, using a mask that
comprised all voxels showing a transdiagnostic alteration in the
ANCOVA. This mask was created using the Neuromorphometrics
atlas (http://www.neuromorphometrics.com/) as implemented in
SPM12. This statistical comparison was carried out using a two-
sample t-test and, once again, statistical inferences were made at
p < 0.05 after FWE correction with a minimum extent threshold of
10 voxels.
RESULTS
There were no regions with lower gray matter volume in patients
relative to HCs across all diagnostic groups. However, the putamen
showed higher gray matter volume in all four psychiatric groups
relative to HC; this effect was evident both in the right (cluster= 32
voxels; x= 32 y= 6 z=−2; z-score: 5.97; p-value < 0.001 after
Fig. 1 Transdiagnostic gray matter increases in patients relative to healthy controls. Left: mean gray matter volume in the ﬁve groups; the
values on the y-axis refer to cubic millimeters per voxel with error bars representing SD. Right: regions of the left and right putamen where
transdiagnostic increases were detected. FEP ﬁrst-episode psychosis, OCD obsessive-compulsive disorder, PTSD post-traumatic stress disorder,
MDD major depressive disorder, HC healthy controls, GMV gray matter volume measured as mm3 of gray matter per voxel
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FWE correction) and the left (cluster= 30 voxels; x=−30 y= 5
z=−7; z-score: 4.97; p-value= 0.001 after FWE correction) hemi-
sphere (Fig. 1).
Next, we considered whether the neuroanatomical increase in
the bilateral putamen of patients relative to HCs was associated
with severity of symptoms. This involved performing partial
correlation analyses between gray matter volume in the left and
right putamen and clinical scores within each diagnostic group,
controlling for age and gender. This revealed signiﬁcant positive
correlations in the whole patient sample as well as in each
individual diagnostic group (Table 2 and Fig. 2); in other words,
higher gray matter volume in the putamen was associated with
higher severity of symptoms.
To elucidate whether the transdiagnostic increase in the
bilateral putamen is a marker of current psychiatric illness or
reﬂected pre-existing familial vulnerability, we performed a region
of interest analysis in 20 unaffected ﬁrst-degree relatives of
patients with a diagnosis of FEP. This involved creating a mask of
the bilateral putamen (total size: 62 voxels) and then performing a
two-sample t-test to compare unaffected relatives and our group
of HCs within this bilateral mask. The putamen showed higher
gray matter volume in the group of unaffected relatives compared
to HCs; this effect was evident both in the left (cluster= 30 voxels;
x=−32 y=−8 z= 2; z-score: 9.39; p-value < 0.001 after FWE
correction) and the right (cluster= 32 voxels; x= 32 y=−6 z= 2;
z-score: 8.13; p-value < 0.001 after FWE correction) hemisphere
Fig. 3.
DISCUSSION
The aim of this study was to test for common underlying
neuroanatomic alterations across several diagnostic categories.
This was achieved by investigating brain structure in medication-
naive individuals with a number of psychiatric disorders, including
schizophrenia, depression, OCD, and PTSD. Our ﬁndings indicated
a transdiagnostic neuroanatomic signature across different
diagnostic categories: an increase in gray matter volume of the
bilateral putamen in all patient groups relative to HCs. The degree
of increase was correlated with symptom severity and was also
evident in unaffected ﬁrst-degree relatives. Critically, as the
individuals included in the current study were all medication-
naive at the time of the scanning, the current results cannot be
explained by medication effects.
Consistent with our ﬁrst hypothesis of transdiagnostic neuroa-
natomical alterations, our investigation revealed higher gray
matter volume of the putamen across all four disorders. The
putamen receives afferent inputs from several cortical regions and
via the thalamus sends neural projections back to the neocortex
Table 2. Association between gray matter volume in the bilateral putamen and severity of symptoms
Right putamen Left putamen
Diagnosis Coordinates Partial correlation Coordinates Partial correlation
All patients 29 9 −8 r= 0.313, p < 0.001 −29 8 −5 r= 0.326, p < 0.001
FEP 28 7 8 r= 0.072, p= 0.731 −27 8 6 r= 0.178, p= 0.042
MDD 26 12 −8 r= 0.240, p= 0.023 −26 10 −5 r= 0.101, p= 0.512
PTSD 32 5 −9 r= 0.247, p= 0.020 −27 9 −8 r= 0.210, p= 0.050
OCD 24 11 0 r= 0.275, p= 0.009 −24 11 1 r= 0.253, p= 0.017
Symptoms were measured using PANSS total score for FEP; HAM-D score for MDD; CAPS score for PTSD; and Y-BOCS total score for OCD patients. The reported
results refers to partial correlations, where age and gender were controlled in the correlation between GM and disease severity.
FEP ﬁrst-episode psychosis, MDD major depressive disorder, PTSD post-traumatic stress disorder, OCD obsessive-compulsive disorder
Fig. 2 Partial correlation between gray matter volume in the right (a) and left (b) putamen and the disease severity, controlling for age and
gender. To ensure disease severity scores were comparable across different disorders, these scores were normalized accordingly within each
diagnostic group with the following formula: normalized individual value= (individual value−minimum score)/(maximum score−minimum
score). Following the application of this formula, the disease severity score of each patient ranged between 0 and 1. GMV gray matter volume
measured as mm3 of gray matter per voxel
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[26]. Through these cortico–striato–thalamo neural loops, the
putamen serves as a center for the integration of high-level
cognitive, motor, and limbic processes [27]. Given its role in these
processes, it is unsurprising that dysregulation of this region is
thought to underlie the emergence of cognitive and clinical
symptoms in psychiatric disease [28]. Previous studies have
reported higher gray matter volume in the putamen of patients
relative to HCs in schizophrenia [29, 30] and OCD [31, 32]. As
dopamine is a key neurotransmitter in the putamen and D2
dopamine receptors are a major target of typical antipsychotic
medications, the observed increases have typically been inter-
preted as a consequence of D2 blockade induced by antipsychotic
medication [33]. However, it is not possible to determine the
functional signiﬁcance of increased putamen volume observed in
the present study. Future studies using healthy high-risk samples,
which systematically map structural and functional indices within
a longitudinal design, are necessary to shed light on what these
observed structural differences may mean at a mechanistic level
of disease progression and presentation.
Consistent with our second hypothesis of an association
between transdiagnostic neuroanatomical alteration and severity
of symptoms, gray matter volume in the putamen was positively
correlated with higher severity of symptoms; this correlation was
evident when considering each diagnostic group separately as
well when combining the four disorders into a single sample (n=
404). A similar positive association between gray matter volume in
the putamen and severity of symptoms had been reported in
individuals with OCD [34] and PTSD [35]; however, to our
knowledge, this is not a common ﬁnding in psychiatric
neuroimaging, and as such requires replication. A previous
investigation had reported a progressive loss of gray matter
volume in the putamen in patients with schizophrenia with poor
long-term outcome relative to those with good long-term
outcome [36]. This had led to the suggestion that putamen
enlargement may be a marker of responsiveness to antipsychotic
treatment and even act as a protective factor against poor long-
term outcome [37]. Our investigation extends this interpretation
by suggesting that higher gray matter volume of the putamen is
associated with a more severe clinical presentation across
diagnostic boundaries. Because disease-speciﬁc clinical scales
were used to measure severity of symptoms in each diagnostic
group, higher gray matter volume of the putamen is likely to
reﬂect generic symptomatology rather than the correlate of
speciﬁc symptoms that are common to all four disorders.
To elucidate whether the transdiagnostic increase in the
bilateral putamen is a marker of current psychiatric illness or
reﬂected pre-existing familial vulnerability we performed a region
of interest analysis in 20 unaffected ﬁrst-degree relatives of
patients with a diagnosis of FEP. Consistent with our third
hypothesis, we detected a signiﬁcant gray matter volume increase
in the left and right putamen within this sample. This suggests
that putamen enlargement is marker of underlying familial
vulnerability rather than the disease itself. Here the term “familial”
refers to effects that are shared between family members, without
necessarily assuming a genetic or environmental etiology.
Taken collectively, our ﬁndings are consistent with emerging
conceptualizations of psychiatric illness, in which each disorder is
best understood as a combination of diagnosis-speciﬁc features and
a transdiagnostic factor reﬂecting general psychopathology [6–9]. In
particular, the observation of putamen enlargement in patients as
well as unaffected relatives provides neurobiological evidence,
which supports conceptualizations of mental illness based on cross-
diagnostic vulnerability [38]. Given the role of the putamen in the
integration of high-level cognitive, motor, and limbic processes, we
speculate that disruption of these processes may represent
a transdiagnostic feature of psychiatric disease. These processes
could therefore be used as target in the development of novel
transdiagnostic interventions aimed a decreasing risk for psycho-
pathology across multiple disorders [10]. We note that the term
“transdiagnostic” can be used to mean “across diagnoses” as well as
“above and beyond diagnosis”. Here we use this term to refer to
effects that are evident across different psychiatric disorders; in
Fig. 3 Transdiagnostic gray matter increases in unaffected relatives relative to healthy controls. Left: mean gray matter volume in the two
groups; the values on the y-axis refer to cubic millimeters per voxel with error bars representing SD. Right: regions of the left and right
putamen where transdiagnostic increases were detected. GMV gray matter volume measured as mm3 of gray matter per voxel
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other words, we are not referring to the idea of abandoning current
categorical categories to go “above and beyond” them (for
interesting discussions on this topic [39, 40]).
A strength of the present investigation is that at the time of
scanning, patients were experiencing their ﬁrst episode of the
illness and were still medication-naive. This means that the effects
reported here cannot be explained by illness chronicity or
medication—two common confounds in neuroimaging studies
of psychiatric disease. A further strength is that all six groups were
scanned using the same MRI scanner and image acquisition
parameters over the same period of time, and therefore our
results cannot be explained by systematic differences in the
acquisition of the data. However, the present investigation has at
least three limitations that warrant careful consideration. First,
although we can exclude medication, age, and gender as potential
confounds, there are other sources of neuroanatomical variability
such as intelligence quotient and socioeconomic status that were
not assessed and which may have contributed to the results.
Second, because the data were acquired using a cross-sectional
rather than a longitudinal design, it was not possible to
unambiguously distinguish between correlates of vulnerability to
psychiatric illness and correlates of psychiatric illness itself.
However, the fact that we did detect a signiﬁcant effect in
unaffected relatives supports the notion that putamen enlarge-
ment is a marker of vulnerability rather than the illness itself. Third,
the group of unaffected relatives (n= 20) was noticeably smaller
than the other ﬁve groups. Nevertheless, we note that a group size
of 20 is considered appropriate for a neuroimaging investigation
[41], and that the bilateral effect detected in this group relative to
HCs would have been statistically signiﬁcant even if we had used a
more conservative whole-brain FWE correction for multiple
comparisons. Finally, while the aim of the present investigation
was to examine common underlying neuroanatomic alterations
across several diagnostic categories, it was not our intention to
assume or imply that there are no disorder-speciﬁc correlates. We
are therefore reporting disease-speciﬁc effects in the Supplemen-
tary Material for completeness (see Supplementary Material).
In conclusion, the present study has revealed putamen
enlargement as a transdiagnostic marker of psychiatric illness;
the observation of this difference in non-affected relatives
suggests that this may reﬂect underlying familial vulnerability to
general psychopathology. This raises the prospect that this
region could be used to assess degree of familial vulnerability
to psychopathology across traditional diagnostic boundaries,
and thus adds to the development of psychoradiology (https://
radiopaedia.org/articles/psychoradiology). These ﬁndings are con-
sistent with emerging conceptualizations of psychiatric illness, in
which each disorder is best understood as a combination of
diagnosis-speciﬁc features and a transdiagnostic factor reﬂecting
general psychopathology [38, 42].
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